Phio Pharmaceuticals Corp. PHIO PHARMA

Q: What is the current share price of Phio Pharmaceuticals Corp. (PHIO)?

As of 2026-09-19 21:16 PDT, Phio Pharmaceuticals Corp. (PHIO) trades at $1.03 on NasdaqCM. Its 52-week range is $0.86 to $2.48.

Q: What is the market capitalisation of PHIO?

Phio Pharmaceuticals Corp. (PHIO) has a market capitalisation of $11.97M on NasdaqCM.

Q: What is the P/E ratio of PHIO?

PHIO trades at a trailing price-to-earnings (P/E) ratio of -0.80. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.95.

Q: What is the return on equity (ROE) of PHIO?

PHIO has a return on equity (ROE) of -113.71%. Its return on capital employed (ROCE) is -45.76%.

Q: Is PHIO a good stock to buy?

This page provides a data-driven analysis of Phio Pharmaceuticals Corp. (PHIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://phiopharma.com

Company Profile ↓

$1.03

-52.97% 1Y

Mkt Cap$11.97M

P/E-0.80

P/B0.95

52W High$2.48

52W Low$0.86

Book Value$1.08

EPS (TTM)$-1.29

Company Overview

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Growth & Price Performance

Stock Price Performance

1 Year:	-52.97%
6 Months:	-14.88%
3 Months:	-5.50%
1 Month:	-0.96%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 10% of range

$0.86 $2.48

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)41.30 · Neutral

Price Performance

1M-0.96%

3M-5.50%

6M-14.88%

1Y-52.97%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Trading 58.5% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.80

Industry PE

24.83

Forward P/E

-1.69

PEG Ratio

Book Value

$1.08

Price to Book

0.95

P/S

EV/EBITDA

0.09

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

Revenue (YoY)

Earnings (YoY)

Profitability & Returns

ROCE

-45.76%

ROE

-113.71%

ROA

-65.77%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.34

EPS (TTM)

$-1.29

Balance Sheet & Liquidity

Debt/Equity

0.00

Quick Ratio

7.62

Current Ratio

8.39

Debt

Total Assets

$14.31M

Current Assets

$17.40M

Working Capital

$20.14M

Ownership

Promoter Holding

3.24%

Chg in Prom Hold

-0.70%

FII / Inst Holding

10.21%

Chg in FII Hold

-0.52%

Financial Snapshot

Enterprise Value

$11.97M

Total Revenue (TTM)

EBITDA

$-13.47M

Free Cash Flow

$-7.72M

Operating Cash Flow

$-12.20M

Shares Outstanding

11.62M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PHIO Phio Pharmaceuticals Corp. PHARMA	1.03	-0.80	$11.97M	0.00%	-45.76%	-113.71%	-	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	29.00K	-	-	34.00K	-	-	10.00K	9.00K	-	-	0	0	23.00K	58.00K	57.00K	21.00K	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.87M	2.31M	2.50M	2.53M	4.17M	-
Operating Income	-2.29M	-2.02M	-2.21M	-2.95M	-2.17M	-2.50M	-2.25M	-2.21M	-2.22M	-7.08M	-2.51M	-2.48M	-2.24M	-1.90M	-1.49M	-2.15M	-2.06M	-2.11M	-2.36M	-1.67M	-2.31M	-3.64M	-2.68M	-3.74M	-2.64M	-2.52M	-3.57M	-3.60M	-2.55M	-2.78M	-2.21M	-1.91M	-1.59M	-	-1.87M	-2.31M	-2.50M	-2.53M	-4.17M	-4.27M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.87M	-2.31M	-2.50M	-2.53M	-4.17M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.77M	-2.17M	-2.39M	-2.37M	-4.00M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-2.28M	-2.01M	-2.21M	-2.94M	-2.17M	-2.50M	-2.23M	-2.21M	-2.21M	-5.46M	-2.51M	-2.48M	-2.24M	-1.90M	-1.49M	-2.12M	-2.04M	-2.09M	-2.35M	-1.67M	-2.31M	-3.41M	-2.69M	-3.74M	-2.64M	-2.53M	-3.58M	-3.60M	-2.55M	-2.78M	-2.15M	-1.85M	-1.52M	-	-1.77M	-2.17M	-2.39M	-2.37M	-4.00M	-4.14M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.32	-0.20	-0.28	-2.34	-2.22	-3.14	-3.15	-13.27	-10.25	-0.47	-3.62	-1.54	-	-0.41	-0.45	-0.44	-	-0.34	-
R&D Expense	1.48M	1.18M	1.46M	2.11M	1.36M	1.73M	1.30M	1.34M	1.46M	1.35M	1.33M	1.49M	1.36M	1.18M	838.00K	1.09M	1.15M	1.04M	1.22M	779.00K	1.26M	2.43M	1.56M	2.67M	1.59M	1.30M	2.51M	2.13M	1.38M	1.81M	1.15M	866.00K	644.00K	-	886.00K	1.07M	1.18M	-	2.79M	3.08M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	97.00K	399.00K	-	34.00K	19.00K	15.00K	138.00K	21.00K	0	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.46M	10.70M	7.39M	9.22M
Operating Income	-	-	-	-	-	-	-	-	-12.77M	-12.97M	-20.95M	-8.83M	-10.24M	-9.02M	-14.06M	-7.36M	-8.99M	-8.79M	-	-11.46M	-10.70M	-7.39M	-9.22M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11.27M	-10.51M	-7.35M	-9.22M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11.48M	-10.83M	-7.15M	-8.70M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-
Net Income	-89.00K	-3.27M	-2.21M	-2.40M	-10.99M	-14.37M	-18.39M	-11.99M	-2.54M	-12.88M	-20.93M	-8.80M	-10.22M	-8.99M	-12.45M	-7.36M	-8.91M	-8.79M	-	-11.48M	-10.83M	-7.15M	-8.70M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-90.86	-46.76	-9.08	-1.45
R&D Expense	-	-	-	-	-	-	-	-	6.62M	10.45M	17.65M	5.68M	6.92M	5.42M	5.37M	4.33M	4.30M	3.72M	8.89M	7.01M	6.33M	3.64M	4.62M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	1.69M	5.59M	14.94M	9.19M	11.16M	13.40M	4.10M	15.32M	8.04M	15.74M	-	12.81M	9.36M	5.74M	21.49M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.45M	9.32M	5.74M	21.48M
Cash & Equivalents	-	-	-	-	-	-	-	-	503.00K	5.13M	11.39M	8.50M	5.12M	12.91M	3.58M	-	-	-	-	11.78M	8.49M	5.38M	21.03M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	2.28M	1.71M	2.08M	-	-	-	-	1.74M	2.29M	2.72M	-	1.98M	1.63M	1.01M	1.34M
Current Liabilities	-	-	-	-	-	-	-	-	1.78M	1.68M	2.08M	1.33M	2.27M	2.54M	2.27M	1.74M	1.88M	2.20M	-	1.94M	1.63M	1.01M	1.34M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	231.00K	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	295.00K	170.00K	35.00K	0	-
Total Equity	-89.00K	-968.00K	-450.00K	2.00K	10.82M	8.97M	741.00K	2.43M	-587.00K	-5.84M	4.94M	2.75M	8.89M	10.86M	1.83M	13.58M	5.75M	13.02M	-	10.84M	7.73M	4.72M	20.15M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	126.56K	416.37K	1.73M	11.62M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-5.06M	-6.31M	-	-	-	-9.51M	-7.52M	-8.64M	-8.80M	-	-12.13M	-10.75M	-7.11M	-7.98M
Investing Cash Flow	16.00K	-3.09M	-	-	-	-103.00K	-5.00K	-72.00K	-19.00K	-	-121.00K	-5.00K	8.00K	-12.00K
Financing Cash Flow	9.67M	15.67M	-	-	-	292.00K	18.82M	772.00K	16.13M	-	-26.00K	7.41M	4.00M	23.64M
Capital Expenditure	-15.00K	-78.00K	-95.00K	-57.00K	-4.00K	-203.00K	-5.00K	-72.00K	-19.00K	-	-121.00K	-5.00K	-1.00K	-12.00K
Free Cash Flow	-5.08M	-6.39M	-	-	-	-9.72M	-7.53M	-8.72M	-8.82M	-	-12.25M	-10.75M	-7.11M	-7.99M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-12.28M	-3.34M	-3.11M	15.65M

Ratios (Annual)

Figures in %.

Metric	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-13,376.3%	-5,250.4%	-	-30,108.8%	-47,447.4%	-93,746.7%	-5,336.2%	-42,795.2%	-	-	-	-	-	-
Net Margin %	-	-	-	-	-	-	-	-	-	-13,278.4%	-5,244.4%	-	-30,067.6%	-47,336.8%	-83,013.3%	-5,333.3%	-42,419.0%	-	-	-	-	-	-
ROE %	100.0%	338.0%	490.9%	-120,250.0%	-101.5%	-160.3%	-2,481.4%	-493.5%	432.2%	220.5%	-423.4%	-320.6%	-115.0%	-82.9%	-679.3%	-54.2%	-155.0%	-67.6%	-	-105.9%	-140.1%	-151.4%	-43.2%
ROCE %	-	-	-	-	-	-	-	-	15,573.2%	-331.6%	-162.9%	-112.4%	-115.2%	-83.0%	-767.2%	-54.2%	-145.9%	-64.9%	-	-105.4%	-138.4%	-156.4%	-45.8%

Shareholding Pattern

Insiders

3.24%

Institutions

10.21%

Public Float

10.55%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Jane Street Group, LLC	1.01%	117.75K	$121.29K
2	Geode Capital Management, LLC	0.99%	114.57K	$118.01K
3	Vanguard Capital Management LLC	0.81%	94.26K	$97.09K
4	Nomura Asset Management International Inc	0.43%	50.00K	$51.50K
5	Cetera Investment Advisers	0.41%	47.50K	$48.92K
6	Citadel Advisors Llc	0.41%	47.15K	$48.56K
7	Vanguard Fiduciary Trust Co	0.33%	38.17K	$39.31K
8	Northern Trust Corporation	0.24%	27.77K	$28.60K
9	Two Sigma Investments, LP	0.19%	21.50K	$22.15K
10	Xtx Topco Ltd	0.16%	18.48K	$19.03K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PHIO

Google News Sat, 22 Aug 2026

PHIO Should I Buy - Intellectia AI

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE5UNE9OR0xJSm00ZHdaZElWcF9Ya2hiQkxRWFNkVEdwazFDc3QyVElwNlJJM2YwNzh0S2VrY1VEYzVEWm5yd0hOc0N3a0RWRGhQOFV5V3B2S0xWQnJpRGc?oc=5" target="_blank">PHIO Should I Buy</a>  <font c…

Google News Wed, 19 Aug 2026

Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHZHS0pyc2VUZm5CaHgyRUpWT0tkdW1aVTBvS19lRDI1NmdqYVhDTWFrR3ZPbjFNb3EzYmh4RHA4NF9aT1BBNmRPWTN2TlphT2g2LThnMTVPNzRaUjhhLUZKeXF4bjlVZVhTSE9SSjI3UmpzS1lCYnk0QmRnaTdMVC1Lc21uRWVRZlFzaW…

Google News hu, 20 Aug 2026

Insider Purchase: Director at $PHIO Buys 15,000 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPU202ZDBFQWtwRjh2QmhkZWJLRUxjM0pjVHA5MmVORkRMMGs0c3VwWWhGRHRMUllBek9xVXVRdnFTMXN3S0puN21JbC1ielpGbXNhcHBmaW0ySmtRZ3FKSXh2bndJcXF2YWxEdXZmdmdGWDlqZzI5YXZqRnIzYWdzbjZyZEZCMHRXQ3pKOV…

Google News ue, 26 May 2026

PHIO - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE04Slh6bk8tWVhMdWZPeENJRWZ2QVpDQV8wUXBJMzBjSnJUU3U1SjdiMzNHVWJxOGZoem44eU1oU0JTWW9TT2c?oc=5" target="_blank">PHIO</a>  <font color="#6f6f6f">Finviz</font>…

Google News Wed, 15 Jul 2026

Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQZUJ1SG1GQlNuY2dHcE80cVladzMyMFNGdEtoUVhYUHRRaWVwLTZ4al9TalQwa1hhTU9YbEM1VjNNVEpoaGNaVkNFazk0dnNOdm5WLWQ0MWJvR3FLRFhzam8tM1R0V1lJeXpoOVlRVDk1TmlyUWZycUVqZy01WEZOOV9ld3daZmNjaFhtR0…

Google News ue, 10 Feb 2026

Phio Pharmaceuticals stock soars after strong cancer treatment results - Investing.com

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOYnowUGhaZTg2bmRSVWhxNjJFZE1BWkVGbklMLXQ5VlRKTE81dDhxUmpxU3RCLWpCNmwxYy01RGFfamNrN3B1eF9TRmVkOVNDQTJLekJKS0VCVFBsVTFwWVJ5WlgybU1jNUJ6U3JfM0lxdFY0LUNoQkRFbUZnQzdsT0F5eGFzS1Z1QmdBZX…

PHIO — Frequently Asked Questions

What is the current share price of Phio Pharmaceuticals Corp. (PHIO)?

As of 2026-09-19 21:16 PDT, Phio Pharmaceuticals Corp. (PHIO) trades at $1.03 on NasdaqCM. Its 52-week range is $0.86 to $2.48.

What is the market capitalisation of PHIO?

Phio Pharmaceuticals Corp. (PHIO) has a market capitalisation of $11.97M on NasdaqCM.

What is the P/E ratio of PHIO?

PHIO trades at a trailing price-to-earnings (P/E) ratio of -0.80. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.95.

What is the return on equity (ROE) of PHIO?

PHIO has a return on equity (ROE) of -113.71%. Its return on capital employed (ROCE) is -45.76%.

Is PHIO a good stock to buy?

This page provides a data-driven analysis of Phio Pharmaceuticals Corp. (PHIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Phio Pharmaceuticals Corp. PHIO PHARMA

Company Overview

Why Investors Should Care

Growth & Price Performance

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

PHIO Should I Buy - Intellectia AI

Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan

Insider Purchase: Director at $PHIO Buys 15,000 Shares - Quiver Quantitative

PHIO - Finviz

Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones - finance.yahoo.com

Phio Pharmaceuticals stock soars after strong cancer treatment results - Investing.com

PHIO — Frequently Asked Questions

What is the current share price of Phio Pharmaceuticals Corp. (PHIO)?

What is the market capitalisation of PHIO?

What is the P/E ratio of PHIO?

What is the return on equity (ROE) of PHIO?

Is PHIO a good stock to buy?

Explore More